Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Channing Capital Management LLC

Channing Capital Management LLC lifted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 165,561 shares of the company’s stock after purchasing an additional 52 shares during the quarter. Channing Capital Management LLC owned approximately 0.54% of Medpace worth $50,749,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in MEDP. RiverPark Advisors LLC purchased a new position in shares of Medpace during the fourth quarter worth about $26,000. Contravisory Investment Management Inc. acquired a new position in shares of Medpace in the fourth quarter valued at approximately $26,000. FinTrust Capital Advisors LLC purchased a new stake in shares of Medpace during the third quarter worth approximately $30,000. GAMMA Investing LLC purchased a new stake in shares of Medpace during the fourth quarter worth approximately $30,000. Finally, McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Medpace during the fourth quarter worth $33,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP traded up $1.50 on Friday, hitting $392.57. 133,312 shares of the company were exchanged, compared to its average volume of 261,284. Medpace Holdings, Inc. has a fifty-two week low of $197.39 and a fifty-two week high of $421.00. The firm has a market capitalization of $12.16 billion, a P/E ratio of 40.02, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40. The business’s fifty day moving average is $398.08 and its 200 day moving average is $331.78.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. The business had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company’s revenue was up 17.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.27 EPS. Analysts forecast that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Guggenheim upped their price objective on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and increased their price target for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price for the company. Finally, Robert W. Baird raised their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $443.00.

Insider Activity

In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. Insiders sold a total of 204,442 shares of company stock worth $82,702,867 over the last 90 days. 20.30% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.